CELL INTELLIGENCE · 肿瘤细胞治疗研究

为体弱和老年骨髓瘤患者定制治疗

Tailoring Therapy for Frail and Elderly Myeloma Patients.

Arlocabtagene autoleucel：一种用于重度预治疗复发/难治性多发性骨髓瘤的靶向 GPRC5D CAR-T 细胞疗法

Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

多发性骨髓瘤中的双特异性抗体与 T 细胞衔接器

Bispecific Antibodies and T-Cell Engagers in Multiple Myeloma.

多发性骨髓瘤与重型 SARS-CoV-2 感染的机制互作：间充质干细胞来源细胞外囊泡的治疗前景

Mechanistic Interplay Between Multiple Myeloma and Severe SARS-CoV-2 Infection: Therapeutic Promise of Mesenchymal Stem Cell-Derived Extracellular Ves

将 B 细胞与浆细胞靶向从肿瘤学转化至自身免疫：模式、定量桥接与开发路线图

Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.

接受抗 CD38 与 BCMA 治疗的多发性骨髓瘤患者中巨细胞病毒再激活的前瞻性研究

Prospective Study of Cytomegalovirus Reactivation in Patients With Multiple Myeloma Receiving Anti-CD38 and BCMA Therapies.

在接受靶向 CD38 和 BCMA 药物的 MM 患者中，低水平 CMV 检出较为常见，但病毒血症通常具有自限性，在我们的研究队列中，尽管 CMV 检出率相对较高，却没有出现有症状的 CMV 感染。

多发性骨髓瘤与拟态：CAR-T 细胞治疗和抗 CD38 单克隆抗体治疗后患者的胃肠道组织学表现

Multiple Myeloma and Mimicry: Gastrointestinal Tract Histologic Findings in Patients Following Chimeric Antigen Receptor T-cell Therapy and Anti-CD38

动态可靶向细胞外囊泡表面蛋白监测 CAR-T 治疗的缓解深度

Dynamic Targetable Extracellular Vesicle Surface Proteins Monitor Depth of Response to CAR T Therapy.

无限可能以及如何利用它们？最佳治疗顺序是什么？

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Ciltacabtagene autoleucel 治疗复发/难治性多发性骨髓瘤的真实世界疗效结局：与 Cartitude-1 试验的比较研究

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.

我们的研究表明，cilta-cel 在真实世界（RW）环境下治疗的 RRMM 患者中疗效相当。